GNRO — Geneuro SA Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Geneuro Completes Patient Recruitment In Temelimab Phase 2 Multiple Sclerosis Trial At The Karolinska Institutet’S Academic Specialist Center
Brief: GeNeuro Gets State Grant For HERV Proteins Research In COVID-19
Brief: Geneuro End-Dec Net Cash Position At 6.8 Million Euros
Brief: Geneuro H1 Net Loss Narrows To EUR 3.9 Mln
Brief: GeNeuro, Karolinska Institutet’s ASC Update On Temelimab Neurodegeneration Prevention Study
Brief: GeNeuro Says Results Of ProTEct-MS Study Expected In 2021
Brief: Geneuro: EUR 10.5 Million In Cash At June 30, 2020
Brief: Geneuro Enrolls First Patient In Temelimab Phase 2 Multiple Sclerosis Trial
Brief: GeNeuro Reports Q1 Net Cash Position Of 11.8 Million Euros
Brief: Geneuro Appoints Dr. David Leppert As Chief Medical Officer
Brief: GeNeuro FY Net Loss Widens To 9.5 Million Euros
Brief: Geneuro Postpones Phase 2 Multiple Sclerosis Trial
Brief: Geneuro Issues New Shares After EUR 17.5 Mln Private Placement
Brief: Geneuro Cash Position At December 31 Of 5.9 Million Euros
Brief: GeNeuro And Karolinska Institutet/Academic Specialist Center To Launch New Clinical Study Of Temelimab
Brief: Geneuro Cash Position Of 8 Million Euros At September 30
Brief: Geneuro H1 Operating Loss Widens to EUR 4.3 Mln
Brief: Geneuro Cash Position Of 10.1 Million Euros At June 30
Brief: GeNeuro: Frontiers In Genetics Review Supports Role Of Hidden DNA Viruses In Neurological Disorders